Literature DB >> 11553217

Two-field dissection is enough for esophageal cancer.

S Law1, J Wong.   

Abstract

Three-field lymphadenectomy for esophageal cancer remains controversial. The high prevalence of cervical lymph node involvement is the basis of cervical lymphadenectomy. Studies of recurrence patterns after esophagectomy, however, indicate that clinically relevant cervical nodal recurrence is uncommon, and that the incidence of such recurrence is similar to that of two-field lymphadenectomy. Moreover, a convincing survival benefit cannot be proven for the more extended lymphadenectomy. The emphasis of three-field lymphadenectomy has shifted to lymphadenectomy of the superior mediastinum and along the recurrent laryngeal nerve chains. Radical dissection of these areas may improve local disease control; the price to pay is increased postoperative morbidity and impaired long-term quality of life. Furthermore, the selection of appropriate patients for extended lymphadenectomy is difficult. Formal three-field lymphadenectomy seems unnecessary, but the controversy of the optimal extent of lymphadenectomy and its impact on survival remains unanswered.

Entities:  

Mesh:

Year:  2001        PMID: 11553217     DOI: 10.1046/j.1442-2050.2001.00164.x

Source DB:  PubMed          Journal:  Dis Esophagus        ISSN: 1120-8694            Impact factor:   3.429


  30 in total

1.  The effects of neoadjuvant chemoradiation on pTNM staging and its prognostic significance in esophageal cancer.

Authors:  Simon Law; Dora L W Kwong; Kam-Ho Wong; Ka-Fai Kwok; John Wong
Journal:  J Gastrointest Surg       Date:  2006-11       Impact factor: 3.452

Review 2.  Current management of esophageal cancer.

Authors:  Simon Law; John Wong
Journal:  J Gastrointest Surg       Date:  2005-02       Impact factor: 3.452

3.  Surgical outcomes in esophageal cancer patients with tumor recurrence after curative esophagectomy.

Authors:  Chikara Kunisaki; Hirochika Makino; Ryo Takagawa; Naoto Yamamoto; Yasuhiko Nagano; Syoichi Fujii; Takashi Kosaka; Hidetaka A Ono; Yuichi Otsuka; Hirotoshi Akiyama; Yasushi Ichikawa; Hiroshi Shimada
Journal:  J Gastrointest Surg       Date:  2007-10-20       Impact factor: 3.452

4.  Recurrence pattern of squamous cell carcinoma in the middle thoracic esophagus after modified Ivor-Lewis esophagectomy.

Authors:  Gang Chen; Zhou Wang; Xiang-Yan Liu; Fan-Ying Liu
Journal:  World J Surg       Date:  2007-05       Impact factor: 3.352

5.  Estimating the need for neck lymphadenectomy in submucosal esophageal cancer using superparamagnetic iron oxide-enhanced magnetic resonance imaging: clinical validation study.

Authors:  Satoru Motoyama; Koichi Ishiyama; Kiyotomi Maruyama; Komei Narita; Yoshihiro Minamiya; Jun-Ichi Ogawa
Journal:  World J Surg       Date:  2012-01       Impact factor: 3.352

6.  Ivor Lewis subtotal esophagectomy with two-field lymphadenectomy for squamous cell carcinoma of the lower thoracic esophagus.

Authors:  Jie Wu; Ying Chai; Xing-Ming Zhou; Qi-Xun Chen; Fu-Lai Yan
Journal:  World J Gastroenterol       Date:  2008-08-28       Impact factor: 5.742

7.  Multicenter prospective randomized trial comparing standard esophagectomy with chemoradiotherapy for treatment of squamous esophageal cancer: early results from the Chinese University Research Group for Esophageal Cancer (CURE).

Authors:  Philip W Y Chiu; Angus C W Chan; S F Leung; H T Leong; K H Kwong; Micheal K W Li; Alex C M Au-Yeung; Sydney C S Chung; Enders K W Ng
Journal:  J Gastrointest Surg       Date:  2005 Jul-Aug       Impact factor: 3.452

8.  Association of the primary tumor location with the site of tumor recurrence after curative resection of thoracic esophageal carcinoma.

Authors:  Yuichiro Doki; Osamu Ishikawa; Ko Takachi; Isao Miyashiro; Yo Sasaki; Hiroaki Ohigashi; Kohei Murata; Terumasa Yamada; Shingo Noura; Hidetoshi Eguchi; Toshiyuki Kabuto; Shingi Imaoka
Journal:  World J Surg       Date:  2005-06       Impact factor: 3.352

9.  Histological regression of squamous esophageal carcinoma assessed by percentage of residual viable cells after neoadjuvant chemoradiation is an important prognostic factor.

Authors:  Daniel King Hung Tong; Simon Law; Dora Lai Wan Kwong; Kwok Wah Chan; Alfred King Yin Lam; Kam Ho Wong
Journal:  Ann Surg Oncol       Date:  2010-03-09       Impact factor: 5.344

10.  Two different surgical approaches in the treatment of adenocarcinoma at the gastroesophageal junction.

Authors:  Jan Johansson; Pauline Djerf; Stefan Oberg; Thomas Zilling; Christer Staël von Holstein; Folke Johnsson; Bruno Walther
Journal:  World J Surg       Date:  2008-06       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.